Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Woessner

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Molecular Pharmaceutics|December 6, 2012
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferationDavid W Woessner, Carol S Lim
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Development of an effective therapy for chronic myelogenous leukemiaDavid W Woessner, Carol S Lim, Michael W Deininger
Molecular Pharmaceutics|August 7, 2013
Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CMLGeoffrey D Miller, David W Woessner, Monika J Sirch, et al.
Molecular Pharmaceutics|September 11, 2012
Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinibJonathan E Constance, David W Woessner, Karina J Matissek, et al.
Nature|August 30, 2008
Functional auditory hair cells produced in the mammalian cochlea by in utero gene transferSamuel P Gubbels, David W Woessner, John C Mitchell, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 8, 2008
Electroporation-mediated gene transfer to the developing mouse inner earJohn V Brigande, Samuel P Gubbels, David W Woessner, et al.
The Journal of Biological Chemistry|June 11, 2011
Disruption of Bcr-Abl coiled coil oligomerization by designAndrew S Dixon, Scott S Pendley, Benjamin J Bruno, et al.
Molecular Pharmaceutics|December 6, 2011
Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosisAndrew S Dixon, Geoffrey D Miller, Benjamin J Bruno, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Molecular Pharmaceutics|December 6, 2012
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferationDavid W Woessner, Carol S Lim
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Development of an effective therapy for chronic myelogenous leukemiaDavid W Woessner, Carol S Lim, Michael W Deininger
Molecular Pharmaceutics|August 7, 2013
Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CMLGeoffrey D Miller, David W Woessner, Monika J Sirch, et al.
Molecular Pharmaceutics|September 11, 2012
Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinibJonathan E Constance, David W Woessner, Karina J Matissek, et al.
Nature|August 30, 2008
Functional auditory hair cells produced in the mammalian cochlea by in utero gene transferSamuel P Gubbels, David W Woessner, John C Mitchell, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 8, 2008
Electroporation-mediated gene transfer to the developing mouse inner earJohn V Brigande, Samuel P Gubbels, David W Woessner, et al.
The Journal of Biological Chemistry|June 11, 2011
Disruption of Bcr-Abl coiled coil oligomerization by designAndrew S Dixon, Scott S Pendley, Benjamin J Bruno, et al.
Molecular Pharmaceutics|December 6, 2011
Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosisAndrew S Dixon, Geoffrey D Miller, Benjamin J Bruno, et al.
Pageof 1